The mission of FUROID is to enable animal-free production of hair (humans), fur (endangered animals) or wool (sheep). The key innovation is the development of continuous and scalable technology, enabling the end of using living animals as a source of fur and wool and dominating the market by 2030. Specifically, we will focus on the development of engineered living fur (ELF), The mission of FUROID is to enable animal-free production of hair (humans), fur (endangered animals) or wool (sheep). The key innovation is the development of continuous and scalable technology, enabling the end of using living animals as a source of fur and wool and dominating the market by 2030. The fundamental innovation will be reached by using a combination of nanostructured scaffolds (RESPILON), hair/wool/fur organoids (GENEUS), and automated biofabrication technologies (BIOFABICS). The ambition of the project is to make significant steps to development of HLM products will deliver set of unprecedent properties: • Animal free-production of fur (ELF) and wool (ELW) without environmental, biodiversity and ethical concerns. • Gene-encoded traceability system endangered species unnoticed, uncontrolled and unpunished endangered species poaching. • Novel vacuum-assisted 3D printing technology overcoming speed of SoA 3D bioprinters • Continuous manufacturing using an automated production system • DBTL platform for rational design and product optimization. • Living human hair follicles (ELH) for transplantation and treatment alopecia as medical and psychological problem. • Fur and wool textiles for apparel industry in rolls without size limitation delivering unprecedent properties. • Improved properties of engineered fur/wool textiles due to nanofiber membranes with regulated water permeability. The project will strengthen the portfolio of ELMs by developing scalable and generalizable technology for forming textured materials in roll-to-roll process from mammalian cells.

Starting from a unique collection of paleo-environmental samples (frozen Arctic soils and sediments) already at AWI and their corresponding ancient DNA (aDNA) metagenomes that stretch back up to a million years, we will retrieve information on how rhizosphere biodiversity and functionality responded to climate changes and extreme events. Preliminary metagenomic data from the collection suggests it is a gold mine of archaic DNA that represents a timeline of adaptions to climate change in the rhizosphere. By reconstructing and analyzing these ancient metagenomes and correlating with available historical climatic change data, we will identify molecular adaptions that impart climate tolerance (specifically resistance to increased temperature and drought). This will be used to i) produce and test engineered root-colonizing bacteria (Pseudomonas fluorescens and Pseudomonas chlororaphis) that will improve climate tolerance of plants (production of humidifying polysaccharides around the root) facilitating the ability to grow on marginal agricultural land (MAL), ii) inform ancestral reconstruction of thermostable and/or cold tolerant enzymes for industrial application and iii) produce engineered Pseudomonas putida strains tailored for bioproduction. For the latter application, we will select genes that encode biomolecules relevant for climate-tolerant phenotypes (humidifying polysaccharides and the biosurfactant betaines). The production of these molecules using biotechnology will be targeted in the project and their application in selected industrial products verified. Target end-user applications will include polysaccharides and betaines for the development of 3D printed organ-on-chip and drug delivery systems as well as the formulation of metalworking fluids, lubricants and industrial cleaning products.

Cardiovascular diseases (CVDs) account for 45% of deaths in Europe and are estimated to cost the EU economy €210 billion a year. However, only four drugs targeting cardiovascular diseases have been approved for use in the last decade. Thus, models that could effectively simulate diseased tissues, would enable the accurate assessment of the efficacy of the pharmaceuticals, and would accelerate drug development are urgently needed. The main bottleneck towards such models is the foetal-like state of the human induced pluripotent stem cell (hiPSC) derived cardiomyocytes (CMs). That is hiPSC-CMs do not reach adult-like maturity. The objective of this project is to produce a platform for growth and maturation of cardiac microtissues for adult-like organotypic models in healthy and diseased states. To achieve that, biomimetic microenvironment that provides all the needed stimuli (electrical, mechanical, topological (3D environment) and biochemical (release of active molecules)), during the maturation of hiPSC-CMs will be developed. This will be achieved by combining electro-mechanoactive polymer-based scaffolds (EMAPS) with bioactive membranes. To characterize the effects of CVD drugs, the contractility of the microtissue will be monitored continuously and simultaneously (over 24-wells) using the sensors developed during the project. To increase the sensitivity and accuracy of the model, deep-learning based algorithms to detect the effects of drugs in vitro will be developed and verified. The goals will be achieved by a multidisciplinary consortium with complementary know-how of three academic units and seven small companies. The increased sensitivity and accuracy of organ-on-chip devices is a needed leap in technology that will accelerate new drug development without the need for animal models; the project aims to provide a platform for the realization of such physiologically-relevant organotypic models.

A healthy, balanced diet has a fundamental role in preventing a large range of chronic diseases and contributes to prolong life quality with obvious benefits for the individual as well as for the society. Aquaculture production plays a substantial role in this perspective because fish is an important source of well-balanced proteins and important nutrients such as marine-derived omega-3 fatty acids. However, its sustainability generates concerns as farmed fish diet is largely based on fishmeal and fish oil. Consumer and environmental groups demand a continued move towards alternative feeds. Objective of this project is to develop a next generation 3D culture platform that accurately mimics the complex functions of the intestinal mucosa. Its purpose is to make available a technology for predicting the health and nutritional value of innovative components of aquafeeds. Current methods are lengthy, expensive and requires the use of large number of animals. Furthermore, they do not provide the knowledge of the cellular and molecular mechanisms determining the final effect of each meal on the fish. This lack of mechanistic knowledge severely limits our capacity to understand and predict the biological value of the single raw material and of their different combinations. We propose to develop new ad hoc biomaterials to create a 3D scaffold where to grow and differentiate a complete population of intestinal epithelial cells. Combining state of the art notions on fish nutrition will lead to a fully functional prototype of artificial intestine (Fish-AI) that will enable the feed industry to predict accurately and efficiently the health and nutritional value of alternative feed sources substantially improving European aquaculture sustainability and competitiveness. The project fosters cross-fertilisation and synergy among nutrition physiology, bioengineering, cell and stem cell biology to develop innovative technologies for a sustainable livestock production.

Recent Nobel Prize-winning discoveries on circadian clock (CC) have laid the foundation for ground-breaking approaches to treat many diseases, including Alzheimer’s disease (AD). AD is a current public health priority. Amplifying the demographic burden of the rising numbers of patients is the low success rate of AD therapies. Given that CC genes regulating memory, sleep, and neurodegeneration have altered expression profiles in AD, CC has recently emerged as a viable therapeutic target for new effective drugs. However, how to develop them remains a fundamental challenge. The “Targeting Circadian Clock Dysfunction in Alzheimer’s Disease” Doctoral Network (TClock4AD) is proposed to create a new generation of researchers able to face such challenge by harnessing neurobiology, medicinal chemistry, pharmaceutical nanotechnology, neuroimmunology, big data, bioinformatics, and entrepreneurship. TClock4AD will exploit unique expertise and advanced technologies at 10 leading universities, 3 research centers, a hospital, 10 non-academic institutions including SMEs, a large pharma company, a Health industry association, and a patient organization across EU, UK, Israel, USA and China. TClock4AD will deliver double degrees to 15 doctoral candidates, with triple-i knowledge/skills, broad vision and a business-oriented mindset. Their research activities will be structured around 5 scientific themes to: (1) develop novel artificial intelligence-, proteolysis targeting chimeras- and multitarget-based strategies for new CC drug candidates (2) develop novel drug delivery nanotechnologies, which take into consideration CC (3) investigate innovative in vitro (stem-cells, 3D cultures) & in vivo (Drosophila), as well as organ-on-chip techniques, for preclinical validation of CC drugs (4) get insight into the molecular mechanisms underlying CC in AD and associated drug response in mice and C. elegans models (5) develop innovative biotech business model and exploitation strategies.